Herasight is a genetic screening company that charges $50,000 to allow hopeful parents to analyze embryos for genetic information like lifespan, height and IQ in life.
Breakdown
- Heracite offers embryo testing that predicts disease risk, lifespan, height, and IQ, allowing parents to select embryos based on these traits. 9s
- The service uses polygenic risk scores and has been used by about 80 couples, with reports costing up to $50,000. 1m 11s
- Critics warn that the technology could increase inequality, as only wealthier families may be able to afford multiple embryo selections. 4m 22s
- Experts caution that predictions for complex traits like IQ have significant uncertainty, with wide possible ranges for outcomes. 5m 54s
- The technology is largely unregulated in the U.S., and other startups are entering the field, raising ongoing ethical and societal debates. 7m 44s